Risk of endometrial cancer following estrogen replacement with and without progestins

Journal of the National Cancer Institute

Volumn 91, Issue 13, 1999, Pages 1131-1137

  Weiderpass, Elisabete ^a   Adami, Hans Olov ^b   Baron, John A ^c   Magnusson, Cecilia ^a   Bergström, Reinhold ^d   Lindgren, Anders ^d   Correia, Nestor ^a   Persson, Ingemar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HARVARD CENTER FOR CANCER PREVENTION   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; GESTAGEN; PROGESTERONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER RISK; CASE CONTROL STUDY; CELL INVASION; CONTROLLED STUDY; DRUG SAFETY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MYOMETRIUM; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; SWEDEN;

EID: 0033532876     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.13.1131     Document Type: Article

References (24)

1. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analyses. Obstet Gynecol 1995;85:304-13.
2. Grady D, Ernster VL. Hormone replacement therapy and endometrial cancer: are current regimens safe? [editorial]. J Natl Cancer Inst 1997;89: 1088-9.
3. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-6.
4. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
5. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298:147-51.
6. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
7. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993;81:265-71.
8. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20-4.
9. Socialstyrelsen. Cancer incidence in Sweden 1995. Stockholm, 1998.
10. Magnusson C, Baron J, Persson I, Wolk A, Bergstrom R, Trichopoulos D, et al. Body size in different periods of life and breast cancer risk in postmenopausal women. Int J Cancer 1998;76:29-34
11. von Schoultz B. Potency of different oestrogen preparations. In: Studd J, Whitehead M, editors. The menopause. London (U.K.): Blackwell Scientific; 1988, p. 130-1.
12. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1 - The analysis of case-control studies. IARC Sci Publ 1980;(32): 192-246.
13. Greenland S. Analysis of polytomous exposures and outcomes. In: Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1998. p.301-28.
14. Grady D, Ernster VL. Endometrial cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 2nd ed. New York (NY): Oxford University Press; 1996. p. 1058-89.
15. Rubin GL, Peterson HB, Lee NC, Macs EF, Wingo PA, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990;162:148-54.
16. Green PK, Weiss NS, McKnight B, Voigt LE, Beresford SA. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 1996;7:575-80.
17. Hirvonen E. Progestins. Maturitas 1996;23 Suppl:S13-8.
18. Shapiro JA, Weiss NS, Beresford SA, Voigt LF. Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 1998; 9:99-101.
19. Key TJ, Beral V. Sex hormones and cancer. In: Vainio H, Magee PN, McGregor DB, McMichel AJ, editors. Mechanisms of carcinogenesis in risk identification. IARC Sci Publ 1992. p. 225-69.
20. Gurpide E. Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst 1991;83:405-16.
21. Hsueh AJ, Peck EJ Jr, Clark JH. Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth. Nature 1975;254:337-9.
22. Tseng L, Gurpide E. Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinol Metab 1975;41:402-4.
23. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502-19.
24. King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986;46:1062-6.